Ipilimumab

Drug Profile

Ipilimumab

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medarex
  • Developer AIO Studien gGmbH; Bavarian Nordic; Bristol-Myers Squibb; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Intergroupe Francophone de Cancerologie Thoracique; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Ono Pharmaceutical; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Brain metastases; Carcinomatous meningitis; CNS cancer; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Adrenal cancer; Liver cancer; Lung cancer; Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 15 Aug 2017 Top-line efficacy data from the phase III CheckMate-214 trial in Renal cell carcinoma released by Bristol-Myers Squibb
  • 27 Jul 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Recurrent) in China (IV) (NCT03195478)
  • 24 Jul 2017 Launched for Malignant melanoma (First-line therapy, In adolescents, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top